Strategies for Screening and Characterizing Targeted Covalent Inhibitors
With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred to as targeted covalent inhibitors (TCIs). In this webinar, experts discuss innovative approaches to screen for covalent binders, strategies for the synthesis of covalent warheads, and assays to optimize the ADME/DMPK properties of these molecules.
This webinar offers a comprehensive perspective on strategies that are crucial for accelerating research focused on covalent drug discovery.
Related Content
Tuberculosis is the leading cause of death from an infectious disease and is caused by Mycobacterium tuberculosis (MTB). Inosine-5′-monophosphate dehydrogenase...
VIEW RESOURCEMutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...
VIEW RESOURCE